Prime Medicine, Inc. (NASDAQ:PRME) is among the 12 Best Genomics Stocks to Invest In. Prime Medicine Announces NEJM Publication Of PM359 Data Prime Medicine, Inc. (NASDAQ:PRME) stated on December 7, 2025, that the New England Journal of Medicine has published Phase 1/2 clinical results for PM359, its experimental autologous hematopoietic stem cell therapy for p47phox chronic granulomatous condition. Prime Editing for p47-phox Chronic Granulomatous Disease is a publication that presents preliminary data f ...